logo-loader
viewDiploma Group Limited

Diploma Group closes $17M construction contract in Mount Pleasant

construction350_536969d34c1de.jpg

Diploma Group (ASX: DGX), a leading Western Australian construction company, has now confirmed the formal award of a contract to undertake the construction of 19 Ogilvie Road Mount Pleasant for $17 million.

The contract is for the construction of a development of 34 residences and office space in Mount Pleasant for new client Norup+Wilson.

The development consists of two basement levels of car park, two commercial levels of office and 7 levels of residences with. Forward works have commenced on site with practical completion expected in June 2015.

This deal is part of $66 million in contract wins last month, which also included a $38 million appointment to construct 109 apartments, and an $11 million Quest Serviced Apartment development.


Analysis

Diploma's construction portfolio has the potential to rapidly build in the near-term, with over $100 million in contracts expected to be announced in the coming weeks.

This has the potential to build on the strong first half results for the six months ending December 2013, with EBIT of $3.3 million on revenue of $111.6 million - which is up 34% on the previous period.

Proactive Investors retains its share price target of $0.047 - $0.054.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Diploma Group Limited

Price: - -

ASX:DGX
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn's therapy used to treat New York coronavirus...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the biotech shared positive test results today from seven coronavirus (COVID-19) patients who were treated with the company’s drug leronlimab at a leading medical center in the New York City area. Pourhassan, together diagnostics...

12 hours, 49 minutes ago

2 min read